Rheumatoid arthritis

New Study Finds People With Inflammatory Arthritis Are More Likely To Seek Mental Health Care

Retrieved on: 
Wednesday, January 24, 2024
Anxiety, Psoriatic arthritis, Rheumatoid arthritis, Ankylosing spondylitis, Inflammatory arthritis, Research, Disease, Conditional sentence, Diagnosis, Depression, Pharmaceutical industry

A recent study conducted by a team of scientists at Arthritis Research Canada has found a link between IA and the need for mental health treatment and medication.

Key Points: 
  • A recent study conducted by a team of scientists at Arthritis Research Canada has found a link between IA and the need for mental health treatment and medication.
  • This research aimed to describe patterns of depression and anxiety health care before and after a diagnosis among people with IA, including: ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis.
  • "The results of this study are revealing, but this is only a starting point," said Dr. Alyssa Howren, Research Trainee at Arthritis Research Canada.
  • "We need additional research to investigate alternative explanations as to why people with inflammatory arthritis have a higher requirement for mental health care and medication."

Antibody Therapeutics Market Size to Grow USD 364180 Million by 2029 at a CAGR of 11% | Valuates Reports

Retrieved on: 
Sunday, January 21, 2024
Conditional sentence, Antibody, Therapy, Research, Lupus, Incidence, Multiple sclerosis, Hook effect, Biotechnology, Rheumatoid arthritis, Immunotherapy, Risk, Infection, Immune system, Medication, USD, Prevalence, Antigen, Engineering, Category, Ageing, Vaccine

Antibody Based Therapeutics Market is projected to reach USD 364180 Million in 2029, increasing from USD 175410 Million in 2022, with a CAGR of 11.0% during the period of 2023 to 2029.

Key Points: 
  • Antibody Based Therapeutics Market is projected to reach USD 364180 Million in 2029, increasing from USD 175410 Million in 2022, with a CAGR of 11.0% during the period of 2023 to 2029.
  • The medical community's rising acceptance of antibody therapies is partly due to their expanding applicability, particularly in cancer and autoimmune illnesses.
  • The market for antibody therapies is expanding due to the rising incidence of chronic illnesses worldwide.
  • The Market for Antibody Therapeutics is dominated by North America because of the region's strong healthcare system, intensive R&D, and high rate of chronic illness.

Antibody Therapeutics Market Size to Grow USD 364180 Million by 2029 at a CAGR of 11% | Valuates Reports

Retrieved on: 
Sunday, January 21, 2024
Conditional sentence, Antibody, Therapy, Research, Lupus, Incidence, Multiple sclerosis, Hook effect, Biotechnology, Rheumatoid arthritis, Immunotherapy, Risk, Infection, Immune system, Medication, USD, Prevalence, Antigen, Engineering, Category, Ageing, Vaccine

Antibody Based Therapeutics Market is projected to reach USD 364180 Million in 2029, increasing from USD 175410 Million in 2022, with a CAGR of 11.0% during the period of 2023 to 2029.

Key Points: 
  • Antibody Based Therapeutics Market is projected to reach USD 364180 Million in 2029, increasing from USD 175410 Million in 2022, with a CAGR of 11.0% during the period of 2023 to 2029.
  • The medical community's rising acceptance of antibody therapies is partly due to their expanding applicability, particularly in cancer and autoimmune illnesses.
  • The market for antibody therapies is expanding due to the rising incidence of chronic illnesses worldwide.
  • The Market for Antibody Therapeutics is dominated by North America because of the region's strong healthcare system, intensive R&D, and high rate of chronic illness.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Dollar General, Estee, VNET, and Assertio and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, January 17, 2024
Facility, Patient, Dollar, EL, Dollar General, Adjustment, Rheumatoid arthritis, Class, ASRT, P.C, Complaint, Executive, Risk, Sale, Spectrum, Theft, Food, Acquisition, EPS, Suppository, FDA, News, Cayman, Defendant, Growth, Cryptocurrency

Then, on March 16, 2023, Dollar General revealed, among other things, that it missed its prior annual net sales guidance by approximately $140 million.

Key Points: 
  • Then, on March 16, 2023, Dollar General revealed, among other things, that it missed its prior annual net sales guidance by approximately $140 million.
  • On this news, the price of Dollar General common stock fell nearly 3%.
  • Thereafter, on June 1, 2023, Dollar General reported first quarter of 2023 revenue of $130 million below analysts’ estimates.
  • On, January 3, 2024, Assertio issued a press release announcing that Defendant Peisert was stepping down from his role as the Company's CEO.

Assertio Holdings, Inc. (ASRT) Class Action Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Assertio Holdings, Inc. Class Action

Retrieved on: 
Tuesday, January 16, 2024
Patient, LLP, Person, Spectrum Pharmaceuticals, Rheumatoid arthritis, ASRT, Risk, Sale, Integration, Spectrum, Acquisition, Suppository, FDA, News

What is this Case About: Assertio Holdings, Inc. (ASRT) Allegedly Misled Investors Regarding its Reliance on Indocin and Integration of Spectrum Pharmaceuticals, Inc.

Key Points: 
  • What is this Case About: Assertio Holdings, Inc. (ASRT) Allegedly Misled Investors Regarding its Reliance on Indocin and Integration of Spectrum Pharmaceuticals, Inc.
  • In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology, along with Spectrum’s injection asset Rolvedon.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Assertio Holdings, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

ASSERTIO HOLDINGS, INC. (NASDAQ: ASRT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Assertio Holdings, Inc.

Retrieved on: 
Tuesday, January 16, 2024
Action Replay, Patient, Spectrum Pharmaceuticals, Rheumatoid arthritis, ASRT, Complaint, Risk, Sale, District court, Court, Spectrum, Advertising, Acquisition, News, Defendant, Security (finance)

If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.

Key Points: 
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 5, 2024.
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Cerebras Collaborates with Mayo Clinic to Advance AI in Healthcare

Retrieved on: 
Monday, January 15, 2024
Health, Technology, Hospitals, Health Technology, Software, Artificial Intelligence, Patient, Health care, DNA, Medicine, AI, Mayo Clinic, Artificial intelligence in healthcare, Disease, Conference, Rheumatoid arthritis, Therapy, GDP, System, Medical device

Cerebras Systems , a pioneer in accelerating generative AI, today announced a collaboration with Mayo Clinic as its first generative AI collaborator for the development of large language models (LLMs) for medical applications.

Key Points: 
  • Cerebras Systems , a pioneer in accelerating generative AI, today announced a collaboration with Mayo Clinic as its first generative AI collaborator for the development of large language models (LLMs) for medical applications.
  • To create the first truly patient-centric healthcare AI, Mayo Clinic selected Cerebras for its proven experience in designing and training large scale, domain-specific generative AI models.
  • Mayo Clinic and Cerebras seek to develop a similar model for other disease states.
  • The Cerebras CS-2, powered by the WSE-2, is purpose-built for generative AI and delivers a rare combination of world-leading AI compute, software and AI expertise.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against VNET, and Assertio and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, January 13, 2024
Learning, Facility, Patient, Adjustment, Spectrum Pharmaceuticals, Rheumatoid arthritis, ASRT, P.C, Complaint, Executive, Risk, Sale, Spectrum, Food, Acquisition, EPS, Suppository, FDA, News, Cayman, Defendant, Cryptocurrency

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • On this news, the Company’s share price fell $0.20, or 3.2% on February 13, 2023, on unusually heavy trading volume.
  • According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Assertio class action go to: https://bespc.com/cases/ASRT

ASSERTIO HOLDINGS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT)

Retrieved on: 
Wednesday, January 10, 2024
Action Replay, Patient, Spectrum Pharmaceuticals, Rheumatoid arthritis, ASRT, Complaint, Risk, Sale, District court, Spectrum, Court, Advertising, Acquisition, News, Defendant, Security (finance)

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) between March 9, 2023 and November 8, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT) between March 9, 2023 and November 8, 2023, inclusive (the “Class Period”).
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • If you purchased or acquired Assertio securities, and/or would like to discuss your legal rights and options please visit Assertio Holdings, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Assertio Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – ASRT

Retrieved on: 
Wednesday, January 10, 2024
Pomerantz, Patient, Person, Prior, Adjustment, Ext, Rheumatoid arthritis, Complaint, Risk, Sale, District court, Court, Spectrum, Food, Acquisition, EPS, Suppository, FDA, Action Replay, News, Pharmaceutical industry

NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT).

Key Points: 
  • NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT).
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Assertio is a commercial pharmaceutical company that purportedly offers differentiated products to patients utilizing a non-personal promotional model.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.